Luzelena Caro, PhD

Gilead Sciences, Inc.

Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-1166) Obeldesivir clinical dose projection for Marburg virus infection post-exposure prophylaxis
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1231) A Phase 1 Open-label, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Obeldesivir in Participants with Normal Renal Function and Renal Impairment
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1232) Dose selection of obeldesivir for clinical evaluation in treatment of adult participants with respiratory syncytial virus infection
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET